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Abstract
MicroRNAs (miRNAs) are non-coding RNAs that regulate gene expression in post-transcriptional fashion, and emerging
studies support their importance in regulating many biological processes, including myogenic differentiation and muscle
development. miR-29 is a promoting factor during myogenesis but its full spectrum of impact on muscle cells has yet to be
explored. Here we describe an analysis of miR-29 affected transcriptome in C2C12 muscle cells using a high throughput
RNA-sequencing platform. The results reveal that miR-29 not only functions to promote myogenic differentiation but also
suppresses the transdifferentiation of myoblasts into myofibroblasts. miR-29 inhibits the fibrogenic differentiation through
down-regulating both extracellular matrix genes and cell adhesion genes. We further demonstrate that miR-29 is under
negative regulation by TGF-beta (TGF-b)–Smad3 signaling via dual mechanisms of both inhibiting MyoD binding and
enhancing Yin Yang 1 (YY1)-recruited Polycomb association. Together, these results identify miR-29 as a pleiotropic
molecule in both myogenic and fibrogenic differentiation of muscle cells.
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Introduction
microRNAs (miRNAs) are non-coding single-stranded RNAs of
21–25 nucleotides and constitute a novel class of gene regulators
that are found in a variety of eukaryotic organisms. miRNAs
negatively regulate their targets at the post-transcriptional level
through binding to their 39 UTRs [1,2].
Mounting evidences support the importance of miRNAs in skeletal
muscle development and muscle related diseases. The process of
skeletal muscle cell differentiation is orchestrated by transcription
factors MyoD, Myf5, myogenin, MRF4, and Mef2. These factors
activate muscle genes to coordinate myoblasts to terminally withdraw
from cell cycle and subsequently fuse into multinucleated myotubes
[3]. A handful of miRNAs were studied in muscle system and proven
to be critical in regulating myogenic differentiation [4]. Previously,
our group identified miR-29 as a pro-myogenic factor [4,5]. In
undifferentiated myoblasts, miR-29 expression is epigenetically
silenced by a repressive complex containing Yin Yang 1 (YY1) and
Polycomb protein, Enhancer of Zeste Homolog 2 (Ezh2), which is
associated to the miR-29 promoter region causing tri-methylation of
histone 3 lysine 27 (H3K27me3). As differentiation ensues, MyoD
replaces the silencing complex causing the derepression of miR-29
transcriptional expression. In turn, the accumulation of miR-29
during differentiation leads to the depletion of YY1 which is also a
repressor of muscle genes. We further demonstrated that this
regulatory circuit is disrupted in Rhabdomyosarcoma which may
contribute to the development of this tumor. These findings suggest
that miR-29 involved circuitries are critical regulator of gene
expression in skeletal muscle cells. Thus, it is our interest to explore
the full spectrum of the influence by miR-29 in these cells and discover
other targets under the control of miR-29.
In addition to the normal myogenic differentiation, muscle
myogenic cells possess the potential to transdifferentiate into other
mesenchymal lineages. For example, Bone Morphogenic Protein
(BMP) signaling triggers C2C12 transdifferentiation into osteoblasts
whereas PPARgamma (PPARc) promotes its adipogenic transdif-
ferentiation [6,7]. Of particular interest, transdifferentiation of
myogenic cells into myofibroblasts was thought to contribute to the
accumulation of Extracellular Matrix (ECM) molecules and the
onset of fibrosis in injured skeletal muscle [8,9]. TGF-beta (TGF-b),
one of the most potent fibrogenic cytokines, has been individuated
as the major inducer of transdifferentiation of myogenic cells into
myofibroblasts as well as muscle fibrogenesis [8,9,10,11]. After
binding to the receptors, TGF-b phosphorylates and activates
downstream mediators, mainly Smad2 and Smad3, inducing their
translocation to the nucleus, where they regulate the expression of
many target genes, including fibrotic genes, through binding to the
Smad Binding Element (SBE) on their promoter/enhancer. In
addition, TGF-b can induce its downstream inhibitory Smad7,
which in turn inhibits Smad2/3 phosphorylation via the negative
feedback mechanisms. The underlying mechanisms mediating the
pro-fibrogenic effect of TGF-b in C2C12 cells were not fully
understood. Both Rho kinase signaling and Notch2 have been
shown to be downstream mediators [10,11].
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33766In addition to its pro-fibrogenic roles, TGF-b is well-
characterized as a potent inhibitor of myogenic differentiation.
Smad3 has been shown to physically interact with MRFs to repress
their transcriptional activity. In particular, Smad3, but not Smad2,
blocks MyoD-mediated transcriptional activation by associating
with bHLH region of MyoD. This interaction interferes with
MyoD/E protein dimerization and cooperative binding to E-boxes
[12]. Very recently, interplay between TGF-b and miR-29 was
discovered in the regulation of myogenic differentiation [13].
TGF-b treatment suppressed the expression of miR-29 which in
turn up-regulates Histone Deacetylase 4 (HDAC4) to inhibit the
myogenic commitment. However, it was not clear how TGF-b
exerts the suppression on miR-29. We therefore sought to
determine whether it is at the transcriptional level through Smad3
and what other factors are involved.
Although it is not known whether miR-29 plays a part in
regulating transdifferentiation of myoblasts into myofibroblasts,
emerging studies implicated miR-29 family in cardiac, liver,
pulmonary, skin and muscle fibrosis [14,15,16,17,18,19]. Multiple
ECM genes such as collagens, fibrillins and elastin
[15,16,17,18,19] are identified as direct targets of miR-29 in
fibroblasts, implicating miR-29 as a potent factor in modulating
ECM modeling and tissue fibrosis. It was shown that intramus-
cular injection of miR-29 into dystrophic muscles down-regulated
collagen expression [19]; however, the cellular mechanisms
underlying this anti-fibrotic action of miR-29 was still obscure.
Furthermore, it was not clear whether miR-29 regulates both the
anti-myogenic and the pro-fibrogenic effect of TGF-b signaling.
We thus investigated the possible involvement of miR-29 during
the conversion of myoblasts into myofibroblasts as well as its
interaction with TGF-b/Smad3 signaling.
In this study, in an effort trying to gain insights into the global
effect of miR-29 on myogenic cells, a transcriptome analysis by
high throughput RNA-sequencing (RNA-seq) was conducted and
the results revealed that miR-29 down-regulates ECM and cell
adhesion genes in addition to promoting the myogenic differen-
tiation, suggesting a role of miR-29 in suppressing fibrogenic
differentiation of myoblasts. Subsequent analyses demonstrated
that indeed miR-29 inhibits C2C12 transdifferentiation into
myofibroblasts by suppressing both collagens and Lims1 (LIM
and senescent cell antigen-like-containing domain protein).
Furthermore, we demonstrated that TGF-b controls both the
pro-myogenic and anti-fibrogenic functions of miR-29. The
inhibition of miR-29 by TGF-b was mediated by Smad3 at the
transcriptional level through both inhibiting MyoD binding and
enhancing YY1/Polycomb recruitment on its promoter region.
Results
Analysis of miR-29 affected transcriptome using RNA-seq
In order to gain insights into the miR-29 mediated events in
muscle cells, we decided to conduct a genome-wide transcriptome
analysis. A C2C12 cell line stably expressing miR-29 was
established by infecting cells with a miR-29 expressing lentivirus.
Analogous to transiently transfected cells [5], these cells differen-
tiated faster than vector transfected negative control (NC) cells
(data not shown). Subsequently, PolyA-tailed mRNAs from control
and miR-29 cells were subjected to transcriptome analysis using a
RNA-seq platform. Compared to traditional microarray-based
analysis of transcriptomes, mRNA-seq provides higher level of
accuracy and broader dynamic ranges and has been proven to be
suitable for assessing the relatively moderate influences that
miRNAs have on their target mRNAs [20]. A total of 26.3
million and 11.4 million raw reads were sequenced from miR-29
and NC samples, respectively, which were then mapped to mouse
NCBIM37.61 mm9 reference genome via Tophat v1.2 [21]. The
majority of reads can be mapped to exonic regions (.10 FPKM)
and much fewer (,0.05 FPKM) in introns and non-coding regions
(Fig. S1), indicating great specificity for expressed mRNA and
rejection of genomic DNA and unspliced pre-mRNA. Cuffdiff
program from Cufflinks package (v1.0.0) [22] was subsequently
employed to identify the differentially expressed genes under a
false discovery rate (FDR) of 5%. As a result, a total of 472 and
739 genes were found to be up- and down-regulated in miR-29
expressing cell line vs NC cell line (Fig. 1A and Table S1 and
Table S2). Subsequent Gene Ontology (GO) analysis with up-
regulated list of genes revealed that the top ranked lists of enriched
GO categories include ‘‘contractile fiber’’, ‘‘contractile fiber part’’,
‘‘sarcomere’’, ‘‘myofibril’’, ‘‘I band’’, ‘‘Z disc’’ (Table S3), which is
in agreement with the previously identified roles of miR-29 in
accelerating muscle regeneration. Strikingly, GO analysis with
down-regulated list of genes revealed an over-representation of
ECM genes presented in GO categories such as ‘‘Extracellular
matrix’’, ‘‘Extracellular matrix part’’, ‘‘Proteinaceous extracellular
matrix’’, ‘‘Collagen’’ et al. (Fig. 1B–C, Fig. S1C and Table S4).
This is in agreement with the emerging reports demonstrating the
pivotal role of miR-29 in ECM remodeling as well as fibrosis of
multiple tissues [15,16,17,18] (Fig. S1D–E). In addition, we
noticed that cell-adhesion genes under GO categories ‘‘Cell
adhesion’’, ‘‘Biological adhesion’’ and ‘‘Focal adhesion’’ represent
another category of genes under significant influence by miR-29
expression (Fig. 1B).
miR-29 suppresses C2C12 myoblast conversion into
myofibroblast through targeting Collagens and Lims1
The decrease of ECM expression in miR-29 expressing cells led
us to hypothesize that miR-29 functions to inhibit the transdiffer-
entiation of C2C12 myoblasts into fibrogenic cells. We reasoned
that myoblasts have the potential to transdifferentiate into
myofibroblasts. However, under normal myogenic differentiation
condition, YY1 regulated miR-29 drives myoblasts fusion into
myotubes [5], suppressing the fibrogenic pathway. To test this
notion, the expression levels of fibrotic markers during C2C12
differentiation were evaluated. qRT-PCR analysis data presented
in Figure 2A showed an up-regulation of Col 1A1, 1A2, Col 3A1
and a-SMA (alpha Smooth Actin) during early myoblast
differentiation (DM 1d), which is in line with the previous findings
from a transcriptional profiling of gene expression changes during
C2C12 differentiation [23]. The early rise of these genes probably
reflected the need of ECM molecules for cell adhesion, motility,
spreading, and anchorage-dependent growth at the early stage of
differentiation. However, the expression levels were significantly
down-regulated in late times of differentiation (day 2 and 4)
concomitant with the up-regulation of myofibrillar genes, Myosin
Heavy Chain (MyHC), alpha Skeletal Actin (a-Actin), Troponin
and Myogenin, suggesting that fibrogenic trans-differentiation of
C2C12 cells was inhibited during terminal myogenic differentia-
tion. In order to assess whether miR-29 is a critical factor in
determining the fate of myoblast differentiation, miR-29 was over-
expressed in C2C12. As anticipated, the myogenic differentiation
was accelerated as assessed by increased expression levels of
Myogenin, MyHC, Troponin and a-Actin (Fig. 2B). However, the
expressions of Col 1A1, Col 1A2, and Col 3A1 were suppressed
(Fig. 2C), suggesting that miR-29 inhibits fibrogenic differentiation
likely through targeting collagens. Interestingly, a-SMA and VIM
were also found to be down-regulated although they are not
predicted to be direct targets of miR-29 by multiple computational
algorithms (data not shown), indicating that miR-29 may control
miR-29 in Myoblast Conversion to Myofibroblast
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miR-29 led to opposite augmenting effect on Col 1A1, Col 1A2
and Col 3A1 expression (Fig. 2D), supporting that collagens are
direct targets of miR-29. This notion was further examined by
using reporters with a fragment of the collagen (Col 1A1, Col 1A2,
Col 3A) 39 UTR containing the miR-29 binding site fused
downstream of the firefly luciferase (Luc) gene. Co-transfections of
the reporter plasmid (WT) with miR-29 caused significant
repressions of luciferase activities (Fig. 2E). This regulation
appeared specific to miR-29 binding since changes in luciferase
activity were not impacted when transfections were repeated with
an irrelevant miRNA, miR-212, or with the miR-29 site deleted
from the collagen 39UTR (Mutant). In addition to miR-29c, the
other two members of miR-29 family, miR-29a and miR-29b
could also target Collagen 39UTR (Fig. S2). Collectively, our
findings suggest that high level of miR-29 is important for driving
myogenic differentiation and loss of miR-29 promotes transdiffer-
entiation of myoblasts into myofibroblasts by targeting Collagens.
Figure 1. Stable over-expression of miR-29 in C2C12 cells down-regulates ECM and cell adhesion genes. (A) Differentially expressed
genes between C2C12 cells stably expressing vector negative control (NC) and miR-29 were determined by RNA-seq. X- and Y-axis represent the log2
based FPKM values for expressed genes in NC and miR-29 samples, respectively. The black dots represent genes with no significant expression
changes between NC and miR-29 samples. The red dots represent genes with significant expression changes. The blue dots represent genes that
have expression signal in only one sample but absent in the other. (B) Over-represented GO terms by GO analysis of down-regulated list of genes. CC:
cellular component; BP: biological process. SP_PIR: a database of protein super-family names; KEGG: Kyoto Encyclopedia of Genes and Genomes. (C)
Coverage plot showing a ,20 kb region encompassing the Collagen 1A1 (Col) gene on chromosome (Chr) 11; the gene structure is shown in blue
below the graph.
doi:10.1371/journal.pone.0033766.g001
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down-regulated in miR-29 expressing cells (Table S4). Among
them, Lims1 (also called PINCH) is a five LIM domain protein
involved in the regulation of integrin-mediated cell adhesion [24].
Interestingly, Lims1 was predicted to contain miR-29 binding sites
in their 39UTR regions (Fig. 2F), indicating that it may be a direct
target of miR-29. Indeed, Lims1 protein was evidently down-
regulated by over-expression of miR-29 in C2C12 cells (Fig. 2G).
The mRNA expression of Lims1 was also down-regulated in miR-
29 expressing cells at all time points of differentiation comparing to
NC cells (Fig. 2H). Knock-down of miR-29, on the other hand, led
to opposite augmenting effect on Lims1 expression (Fig. 2I).
Additionally, activities of the reporter with Lims1 binding site were
significantly inhibited by miR-29 expression while mutation of this
site abolished the inhibition (Fig. 2J). Together, these data
demonstrate that Lims1 is a direct target of miR-29.
TGF-b suppresses miR-29 expression during myoblast
conversion to myofibroblast
Having gained insights into the role of miR-29 during the
conversion of myoblasts to myofibroblasts, we now turned our
attention to its upstream regulator by asking: what leads to the
down-regulation of miR-29 in this process? TGF-b has been
individuated as the major inducer of myogenic cell into fibrogenic
cells but the underlying mechanism is still largely obscure. We thus
speculated that the pro-fibrogenic action of TGF-b mediated
through miR-29 represents a novel signaling event contributing to
fibrogenic conversion of myoblasts.
Subsequently, the effects of TGF-b in myogenic and fibrogenic
differentiation of C2C12 cells were evaluated. In agreement with
previous finding [10], TGF-b treatment of C2C12 cells led to
significant delay of myogenic program whereas the expressions of
a number of fibrotic genes were increased (Fig. S3A–E). Further IF
staining revealed that TGF-b treatment induced a loss of MyoD
whereas the a-SMA is increased. In addition, both cell
proliferation rate and cell mobility were increased (Fig. S3F–G).
These results indicated a conversion of C2C12 to myofibroblasts.
As shown in Figure 3A, very low level of a-SMA was detected in
untreated cells where MyoD is highly expressed. However, under
TGF-b treatment, a-SMA staining was induced and cells exhibited
typical a-SMA filament bundles characteristic of myofibroblasts
(Fig. 3A and Fig. S3H). We noticed that the cells with strong a-
SMA signal completely lost MyoD (a-SMA+/MyoD2) and also
assumed a myofibroblast morphology with large and more spread-
out looks (Fig. 3A, cells inside the dashed oval), but those with
weak a-SMA signal still maintain MyoD staining (a-SMA+/
MyoD+, Fig. 3A, arrow), probably representing an intermediate
stage during the conversion. Together, these data suggest that
myogenic and fibrogenic differentiations represent two opposite
fates of myoblasts; TGF-b promotes the fibrogenic differentiation
of C2C12 while suppressing the myogenic program. This is inverse
to the effect of miR-29 (Fig. 2), suggesting that TGF-b may
function upstream of miR-29 as a suppressor.
Next, the potential inhibitory role of TGF-b on miR-29 was
examined. Results demonstrated that TGF-b treatment (+)
markedly reduced miR-29 expression (Fig. 3B). Furthermore, it
exerted a dose-dependent inhibition on miR-29 promoter
activities (Fig. 3C), suggesting that the inhibition could be at the
transcriptional level through direct action on miR-29 promoter.
Next, we sought to determine whether TGF-b repression is
biologically functional in terms of regulating the pro-myogenic and
anti-fibrogenic action of miR-29. As expected, miR-29 stable cells
(Fig. 3D, Lane 5–8) displayed accelerated myogenic differentiation
vs NC cells (Lane 1–4). TGF-b treatment led to an obvious delay
in the myogenic program in both NC (Lane 9–12) and miR-29
(Lane 13–16) cells, suggesting that TGF-b acts upstream of miR-
29 in antagonizing its pro-myogenic action. Although the addition
of miR-29 oligos rescued the anti-myogenic effect of TGF-b,i ti s
still largely existent. This implicates that other downstream
pathways could also mediate the effect of TGF-b. The above
Western blotting data were also supported by IF staining of
MyHC (Fig. 3E) and RNA analysis of myogenic markers (Fig. S3I).
In a similar fashion, we examined the effect of TGF-b on the anti-
fibrogenic action of miR-29. Expectedly, TGF-b treatment
abrogated the suppression of miR-29 on Collagens and a-SMA
as well as Lims1 (Fig. 3F–H). Together, these data support that
TGF-b acts upstream of miR-29 to antagonize its pro-myogenic
and anti-fibrogenic effect in C2C12. On the other hand, miR-29
partially attenuates both the pro-fibrogenic and anti-myogenic
actions of TGF-b.
TGF-b repression on miR-29 promoter is transcriptionally
mediated by Smad3
Given that Smad proteins transmit most of the transcriptional
effect exerted by TGF-b, subsequently we examined their
involvement in the down-regulation of miR-29. For this purpose,
myoblasts transfected with specific siRNAs, capable of attenuating
the expressions of Smad2, Smad3, or Smad7 (Fig. 4A), were tested
for the responsiveness to TGF-b in regard to inhibiting miR-29. As
shown in Figure 4B–C, knockdown of Smad3 but not Smad2
Figure 2. miR-29 is anti-fibrogenic in C2C12 cells. (A) C2C12 cells were differentiated (DM) for 0, 1, 2 or 4 days, at which times total RNAs were
isolated for qRT-PCR measurement of the expressions of Col 1A1, Col 1A2, Col 3A1, a-SMA or VIM as well as MyHC, a-Actin, Troponin and MyoG.
Expression folds are shown with respect to 0 hr cells where normalized copy numbers were set to 1. Data are plotted as mean 6 S.D. (B and C) C2C12
cells were transfected with negative control (NC) or miR-29 oligos and differentiated for 48 hrs, at which time total RNAs were isolated for qRT-PCR
measurement of the expressions of Myogenin, Troponin, a-Actin or MyHC as well as Col 1A1, Col 1A2, Col 3A1, a-SMA or VIM. Expression folds are
shown with respect to NC cells where normalized copy numbers were set to 1. Data are plotted as mean 6 S.D. (D) C2C12 cells were transfected with
negative control (Anti-NC) or Anti-miR-29 oligos and differentiated for 48 hrs, at which time total RNAs were isolated for qRT-PCR measurement of
the expressions of Col 1A1, Col 1A2, and Col 3A1. Expression folds are shown with respect to Anti-NC cells where normalized copy numbers were set
to 1. Data are plotted as mean 6 S.D. (E) Wild type (WT) or Mutant Col 1A1, Col 1A2, or Col 3A1-39UTR luciferase reporter constructs were transfected
into C2C12 cells with indicated miRNA or negative control (NC) oligos. Luciferase activities were determined at 48 h post-transfection and normalized
to b-Galactosidase protein. Relative luciferase unit (RLU) is shown with respect to NC cells where normalized luciferase values were set to 1. The data
represent the average of three independent experiments 6 S.D. (F) A schematic illustration of base pairing between mmu-miR-29c with 3078–3099
region on 39UTR of mouse Lims1. (G) Lims1 protein expression was measured in NC or miR-29 stable C2C12 cells by Western blotting using GAPDH as
a loading control. (H) NC or miR-29 stable cells were differentiated and Lims1 expression levels were measured at the indicated time points. (I) C2C12
cells were transfected with negative control (Anti-NC) or Anti-miR-29 oligos and differentiated for 48 hrs, at which time total RNAs were isolated for
qRT-PCR measurement of the expressions of Lims1. Expression folds are shown with respect to Anti-NC cells where normalized copy numbers were
set to 1. Data are plotted as mean 6 S.D. (J) Wild type (WT) or Mutant Lims1-39UTR luciferase reporter constructs were transfected into C2C12 cells
with miR-29 or negative control (NC) oligos. Luciferase activities were determined at 48 h post-transfection and normalized to b-Galactosidase
protein.
doi:10.1371/journal.pone.0033766.g002
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miR-29 promoter activity. In contrast, knockdown of Smad7, an
inhibitor of Smad3 activation, enhanced the inhibition of TGF-b
on miR-29 expression and promoter activity. To substantiate this
finding, primary myoblasts were isolated from tibialis anterior
muscles of wild type (Smad3
+/+), Smad3 heterozygous (Smad3
+/2)
or knockout (Smad3
2/2) mice and examined for miR-29
expression. In agreement, miR-29 expression levels were signifi-
cantly elevated in Smad3
2/2 myoblasts (Figure 4D, 7.360.1 fold,
p,0.0001) compared to Smad3
+/+ cells. Only mild increase (1.9
fold, p,0.01) was detected in Smad3
+/2 cells, suggesting a Smad3
dose-dependent regulation on miR-29 expression. On the
contrary, primary myoblasts isolated from Smad7
2/2 mice
displayed a significant reduction on miR-29 level (Figure 4E,
0.1160.2 fold, p,0.001). Additionally, when injected with
Cardiotoxin, a snake venom that induces extensive muscle necrotic
injury and subsequent regeneration, a steady increase of miR-29
levels were observed during the course of degeneration and
regeneration (day 1, 2, 4, 6, 9) in Smad7
+/+ muscles while Smad7
2/2
mice displayed much lower levels of miR-29 expression at all time
points examined (Fig. 4F). These results reaffirm that Smad3 and
Smad7 are critical mediators of TGF-b inhibition on miR-29.
Interestingly, Smad3 protein was inhibited by miR-29 over-
expression but increased upon miR-29 knock-down in C2C12 cells
(Fig. S4), suggesting miR-29 regulates Smad3 expression although it
is not predicted to be a direct target of miR-29. This is in line with a
recent report showing miR-29 suppresses basal Smad3 expression
possibly through inhibiting TGF-b3 [13].
Interestingly, most studies on Smads have documented their
role as transcriptional activators, although TGF-b signaling often
results in down-regulation of gene expression. We were thus
intrigued to explore the underlying mechanisms through which
Smad3 represses miR-29 transcriptional activity. To test whether
Smad3 can directly bind to miR-29 promoter, we searched for its
binding site on miR-29b/c promoter [5]. Indeed, three SBEs were
discovered in the proximal promoter region (24849, 22741, and
2692 bp upstream of the transcriptional start site). Next, using
ChIP-PCR assays, we detected an induction of Smad3 binding by
TGF-b treatment at all three predicted SBEs (Fig. 4G), indicating
a TGF-b-induced Smad3 nuclear translocation and subsequent
association to miR-29 promoter.
Smad3 regulates miR-29 promoter through inhibiting
MyoD binding and enhancing YY1/Polycomb
recruitment
Previously, Liu et al. demonstrated that Smad3 inhibits MyoD
transcriptional activity through disruption of its binding to E-box
sites of muscle genes [12]. We thus asked whether Smad3
repression on miR-29 promoter could be executed in a similar
fashion as MyoD has been implicated as an activator of miR-29 at
the onset of myogenic differentiation [5]. Four putative MyoD
binding E-boxes were identified (Fig. 5A, M1, M2, M3 and M4).
As shown in Figure 5B, an association of MyoD with these sites
was detected in differentiated myotubes without TGF-b treatment.
However, the binding was largely suppressed by TGF-b.I n
addition to MyoD regulation, we have previously demonstrated
that miR-29 promoter is epigenetically silenced in undifferentiated
myoblasts by an YY1/Polycomb repressive complex through
recruitment to an YY1 binding CCAT box, and removal of this
complex is necessary for the myogenic program to occur [25]. This
promoted us to ask whether TGF-b silencing miR-29 can be
mediated by YY1/Polycomb complex. A search for putative YY1
binding sites uncovered a total of six sites (Fig. 5A, Y1–Y6).
According to our previous findings [5], Y6 was competent for YY1
binding in undifferentiated myoblasts whereas Y3, Y4, Y5 were
not. Y1 and Y2 represent two new sites previously untested.
Subsequent ChIP-PCR assays revealed no enrichment of YY1 on
any site in differentiated cells without TGF-b treatment (Fig. 5C),
which is in agreement with the activation status of miR-29.
However, an increase of enrichment was found at Y1, Y2, Y3 and
Y6 after TGF-b treatment, indicating that TGF-b indeed
enhanced YY1 binding on multiple locations. Yet, no binding
on Y4 and Y5 was detected in both untreated and treated cells
(data not shown). Additional ChIP-PCR assays showed marked
increase of Ezh2 binding at all four YY1 sites (Fig. 5D);
consequently, increased levels of H3K27me3 were detected
(Fig. 5E), suggesting that TGF-b treatment stabilizes YY1 binding
and recruitment of Ezh2 and subsequent histone modification on
multiple regions, which leads to silencing of miR-29 promoter. To
substantiate the above findings from ChIP assays, reporter assays
using miR-29-promoter-Luc plasmid were performed. As shown
in Figure 5F, ectopic expression of YY1 repressed miR-29 reporter
activities and the repression is enhanced with co-transfection of
Smad3 at a dose-dependent manner, suggesting a repressive
synergy between YY1 and Smad3. Ectopic expression of MyoD,
on the other hand, strongly trans-activated the reporter, and this
activation was repressed by Smad3 co-expression at a dose-
dependent manner (Fig. 5G), suggesting Smad3 inhibits MyoD
activation. Moreover, addition of YY1 further abrogated MyoD
activation (Fig. 5H), indicating that the two mechanisms probably
co-act. Collectively, the above results suggest the inhibitory action
of TGF-b/Smad3 on miR-29 transcription is exerted through dual
mechanisms by blocking MyoD binding and enhancing YY1/
Ezh2 association. In keeping with the earlier findings, we found
that knockdown of either Smad3 or YY1 down-regulated Lims1
expression whereas knockdown of MyoD up-regulated its
expression, suggesting Lims1 is under regulation of TGF-b/
Smad3/YY1/MyoD axis (Fig. 5I).
Discussion
In the current study, we present evidences for the pleiotropic
roles of miR-29 in skeletal muscle cells. To our knowledge, this is
the first report to describe the global effects of miR-29 on cellular
transcriptome. In line with a previous study analyzing transcrip-
tome and targetome of miR-155 expressing cells, our results
Figure 3. TGF-b inhibits miR-29 during myogenic and fibrogenic differentiation of C2C12 cells. (A) IF staining of MyoD (red) and a-SMA
(green) in C2C12 cells treated with or without TGF-b. Photos were taken by confocal scanning microscope. Dashed oval is used to circle a-SMA+/
MyoD2 cells; arrow, a-SMA+/MyoD+ cell. Scale bar=50 mm. (B) miR-29 expressions in C2C12 incubated without (2) or with (+) TGF-b for 0, 3 or 6
days in DM. (C) miR-29 promoter luciferease reporter activities in C2C12 incubated with indicated doses of TGF-b for 48 hrs in DM. (D) C2C12 cells
stably expressing miR-29 or vector control (NC) were treated with TGF-b in DM for 0, 2, 4, or 6 days at which times MyHC, Troponin, a-Actin were
probed by Western blotting. (E) Cells were photographed under phase contrast or immunostained for MyHC and visualized by confocal scanning
microscope at DM day 4. Positively stained cells were quantified. Data are plotted as mean 6 S.D. Scale bars=50 mm. (F) NC or miR-29 stable cells
were treated without or with TGF-b for 48 hrs at which time Col 1, a-SMA and Lims1 were probed by Western blotting with a-Tubulin as a loading
control. (G) Col 1, a-SMA, VIM and Lims1 were stained by IF and visualized by confocal scanning microscope. Scale bars=50 mm. (H) mRNA
expressions of Col 1A1, Col 3A1, a-SMA and Lims1. Data are plotted as mean 6 S.D. *p,0.05.
doi:10.1371/journal.pone.0033766.g003
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determine the overall cascade of events under influence by
miRNA. Its broader dynamic range allows the analysis of both
high- and low-abundance transcripts and facilitates the analysis of
genes spanning a wide spectrum of expression levels. Our results
reveal that in addition to promoting myogenic differentiation,
miR-29 inhibits the expression of a large number of ECM genes
including Collagens, MATN1, ECM1 (Tables S2 and S4). This is
in line with others’ results and led us to believe that miR-29
inhibits the transdifferentiation of myoblasts into myofibroblasts.
In addition to ECM genes, we found that cell adhesion genes
represent an important category of genes under control by miR-
Figure 4. Smad3 mediates the repression of TGF-b on miR-29 at the transcriptional level by binding to miR-29 promoter region. (A)
C2C12 myoblasts were transfected with siRNA oligos against Smad2, Smad3 or Smad7, using scrambled siRNAs (SCR) as a control. 48 hr post-
transfection, the expressions were examined by Western blotting using a-Tubulin as a loading control. (B) C2C12 myoblasts, transfected with the
indicated siRNA oligos, were incubated with TGF-b in DM for 48 hrs at which time the expressions of miR-29 were measured. (C) miR-29-promoter-luc
reporter activities in C2C12 myoblasts transfected with the above siRNA oligos and then treated with TGF-b in DM for 48 hrs. (D) miR-29 expressions
in primary myoblasts isolated from Smad3
+/+, Smad3
+/2 or Smad3





2/2 mice were injected with Cardiotoxin (CTX) into TA muscles to induce muscle regeneration. Muscles were harvested at
designated days after the injection and assayed for miR-29 expression levels by qRT-PCR. (G) C2C12 myoblasts were untreated or treated with TGF-b
for 12 hrs at which time chromatins were collected for ChIP assays using antibodies against Smad3 or IgG as controls. PCR assays were then used to
measure the enrichment fold of Smad3 on three putative binding sites, S1, S2 and S3.
doi:10.1371/journal.pone.0033766.g004
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PLoS ONE | www.plosone.org 8 March 2012 | Volume 7 | Issue 3 | e33766Figure 5. Smad3 suppresses miR-29 promoter through inhibiting MyoD binding and enhancing YY1 recruitment. (A) Schematic
illustration of proximal promoter region of mmu-miR-29b/c primary transcript. The arrow denotes the Transcriptional Start Site (TSS). Predicted
Smad3 (S), MyoD (M) and YY1 (Y) binding sites were displayed. The location of each site was indicated below. (B) C2C12 myoblasts were untreated or
treated with TGF-b for 12 hrs at which time chromatins were collected for ChIP assays using antibodies against MyoD or IgG as controls. PCR assays
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direct target of miR-29. Considering that myofibroblast differen-
tiation is dependent on cell adhesion [26,27], down-regulation of
Lims1 probably mediates the suppressive role of miR-29 during
myoblast conversion to myofibroblast. These data thus add a novel
target to the growing list of miR-29 targets, and implicate miR-29
as a potent regulator in many cellular processes involving cell
adhesion factors such as cell migration, cell invasion and cell
survival. Collectively, our transcriptome analysis demonstrated
that the two main functions of miR-29 in muscle development are
to increase myogenic differentiation and to suppress fibrogenic
differentiation.
As the major inducer of fibrotic cascade, TGF-b signaling has
been shown to induce the conversion of C2C12 into myofibro-
blasts while inhibiting the myogenic differentiation. The down-
stream molecular mechanisms are not fully understood. Our
studies identify a novel pathway through which miR-29 regulates
TGF-b signaling induced transdifferentiation. In line with a recent
study demonstrating that TGF-b controls miR-29 to inhibit
myogenic differentiation [13], we also found that TGF-b can
attenuate the pro-myogenic actions of miR-29. Our results,
however, for the first time demonstrated that miR-29 also
regulates TGF-b induced transdifferentiation, thus establishing
the dual roles of TGF-b-miR-29 axis in both myogenic and
fibrogenic differentiation of muscle cells. Our findings provide
novel insights in understanding the pathologic fibrosis of skeletal
muscle. Muscle fibrosis is a major pathological hallmark of chronic
myopathies most often muscular dystrophies, which are inherited
disorders characterized by muscle degeneration and associated
progressive wasting and weakness. In the most severe cases, such
as Duchenne muscular dystrophy (DMD), the absence of
dystrophin protein leads to sarcolemmar permeability, influx of
calcium, and activation of proteases to cause myofiber necrosis
and degeneration. This is followed to some extent by regeneration
but the complete regeneration is prevented by excessive synthesis
and deposition of ECM proteins, which eventually leads to fibrosis
[28,29,30]. Thus, fibrosis is a prominent pathological hallmark of
skeletal muscle in patients with DMD and contributes to
progressive muscle dysfunction and the lethal phenotype of
DMD [31,32]. Unfortunately, the molecular mechanisms under-
lying muscle fibrogenesis is not fully understood. TGF-b signaling
is elevated in dystrophic muscles and is speculated to be the major
inducer of muscle fibrogenesis but the underlying mechanisms are
still unclear. Interestingly, miR-29 was found to be down-regulated
in dystrophic muscles in concomitant with the increased TGF-b
signaling (our unpublished data). Our findings thus fuels the
interesting hypothesis that loss of miR-29 through TGF-b
signaling promotes transdifferentiation of myoblasts into myofi-
broblasts, which represents a novel contributing route to muscle
fibrogenesis in dystrophic muscles. Very recently, Ardite E. et al
discovered that miR-21 is also involved in fibrosis of DMD [33],
highlighting the critical roles that miRNAs in general play in
muscle fibrogenesis.
It is believed that Smad proteins mediate gene activation or
repression as a result of promoter-specific interactions with
transcriptional activators or co-repressors which compensate for
its weak intrinsic binding affinity for their target elements (SBE). In
contrast to the well-documented cooperation of Smads with
sequence-specific factors to activate transcription, the mechanisms
underlying Smad-mediated transcriptional repression are only
beginning to emerge [12,34,35]. Here we uncover a novel
mechanism by which Smad3 exerts its function through synergetic
interfering with MyoD association and harnessing YY1/Ezh2
repressive complex. Previously, Liu et al demonstrated that Smad3
acts downstream of TGF-b to repress MyoD-dependent activation
through physically interacting with MyoD thus interfering with its
formation of an active MyoD/E protein complex and its
subsequent binding to multimerized E-box sequence [12,35]. In
agreement with the above findings, our results also revealed
disengagement of MyoD from multiple E-boxes with TGF-b
activation of Smad3 binding. Furthermore, in our case, inhibition
of MyoD binding on miR-29 promoter seems to be dependent on
Smad3 association with proximal SBE as all the identified E-boxes
are in the vicinity of SBEs (Fig. 5A). In addition to the above
mechanism, we present evidence for a new layer of repression
through recruitment of YY1/Ezh2 repressive complex on multiple
sites of miR-29 promoter. Given that three of the four YY1
binding sites, Y2, Y3, and Y6 (Fig. 5A), are not adjacent to SBEs, it
is very likely that the recruitment is independent on Smad3
binding. Nevertheless, one of the identified YY1 sites, Y1, was very
close to a SBE, S1, suggesting that additional mechanism
dependent on Smad3 binding may exist. Further studies are
needed to test the above hypotheses. Therefore, the above two
modes of actions exert reinforcing levels of control on miR-29
transcription, ensuring its down-regulation during the fibrogenic
differentiation of myoblasts. The application of this new
mechanism may extend beyond miR-29 promoter and represent
a general mode of TGF-b/Smad3 repression in skeletal muscle
differentiation considering many myofibrillar genes were also
regulated by MyoD and YY1/Ezh2 complex [5,25]. Together
with others’ findings, our data suggest that diverse mechanisms
lead to transcriptional repression in response to TGF-b.
Taken together, our results identified miR-29 as a pleiotropic
molecule in muscle cells. As modeled in Figure 6, during normal
muscle regeneration, miR-29 level is elevated through replacing a
repressive YY1/Ezh2/HDAC1 complex by a MyoD/SRF
activating complex on its promoter, leading to successful myogenic
differentiation [5]; However, during the transdifferentiation,
activated TGF-b signaling induces Smad3 translocation into
nucleus where it binds to miR-29 promoter, resulting in MyoD
dissociation as well as YY1/Ezh2 stabilization. This causes a loss
of miR-29 expression and increased expression of Collagens and




Mouse C2C12 myoblasts were obtained from ATCC and
cultured in DMEM supplemented with 10% FBS, 2 mM L-
were then used to measure the enrichment fold of MyoD on four putative binding sites, M1/M2, M3 and M4. (C, D and E) ChIP-PCR assays were
performed as above to examine the binding of YY1, Ezh2 and H3K27me3 to putative YY1 binding sites, Y1, Y2, Y3 or Y6. Enrichment folds are shown
with respect to IgG control where normalized PCR values were set to 1. Data are plotted as mean 6 S.D. (F) Upper: 10T1/2 cells were transfected with
0.25 mg of miR-29-promoter-luc reporter plasmid along with 0.5 mg YY1 plasmid and Smad3 plasmid (0, 0.20, 0.50, 1.00, or 2.00 mg). 24 hr post-
transfection, cells were treated with TGF-b for 48 hrs at which time luciferase activities were determined. (G) The transfections were performed as
above with 0.5 mg of MyoD plasmid and Smad3 expression plasmid (0, 0.20, 0.50, 1.00, or 2.00 mg). (H) The transfections were performed as above
with indicated plasmids (0.5 mg of MyoD, YY1 or Smad3 plasmids were used). (I) C2C12 cells were transfected with siRNA oligos knocking down
Smad3, MyoD or YY1. The expression of Lims1 was examined by Western blotting using Tubulin as a loading control. *p,0.05. ** p,0.01.
doi:10.1371/journal.pone.0033766.g005
miR-29 in Myoblast Conversion to Myofibroblast
PLoS ONE | www.plosone.org 10 March 2012 | Volume 7 | Issue 3 | e33766glutamine, 100 U/ml penicillin, and 100 mg of Streptomycin at 37
Ci n5 %C O 2. For myofibroblast transdifferentiation and
myogenic differentiation experiments, cells were seeded in
60 mm or 100 mm plates and when 90% confluent they were
shifted to DMEM without FBS containing 2% horse serum. Cells
were treated with 5 ng/ml TGF-b1 (R&D systems). 10T1/2 cells
and HEK 293T cells were cultured in DMEM supplemented with
10% FBS.
Transfections and infections
Transient transfections with miRNA precursor oligos and
siRNA oligos or DNA plasmids were performed in 60 mm or
100 mm dishes with Lipofectamine 2000 reagent as suggested by
the manufacturer (Invitrogen). For luciferase experiments, C2C12
and primary myoblasts were transfected in 12-well plates. Cell
extracts were prepared and luciferase activity was monitored as
previously described [36] or using dual-luciferase kit (Promega).
To produce virus particles expressing vector or miR-29, pMIF-
cGFP-Zeo Vector or pMIF-cGFP-Zeo-miR-29 plasmids along
with the packaging plasmid mix (pPACK) (System Biosciences)
were transfected into HEK293T cells maintained in 10% FBS.
48 h after transfection, supernatant was harvested from these cells
and viral titers were estimated by FACS analysis. Approximately
1610
9 virus particles were used to transduce C2C12 cells, which
were subsequently placed in 400 mg/ml Zeocin for stable selection.
Stable clones were pooled together after ,2 week selection.
Oligonucleotides
Precursor miRNA oligos were obtained from Ambion. Mercury
LNA microRNA or control oligos were obtained from Exiqon.
The 19-nucleotide siRNA duplexes against mouse Smad 2 coding
region (siRNA, 59-GAAUUGAGCCACAGAGUAA-39), Smad 3
coding region (siRNA, 59-CAGUUCUACCUCCAGUGUU-39)
or Smad 7 coding region (siRNA, 59-GCACUCGGUGCUCAA-
GAAA-39) or scrambled oligos were obtained from Ribobio. In
each case 50 mM oligos were used for transient transfections into
cells.
DNA constructs
Col 1A1-3UTR, Col 1A2-3 UTR, Col 3A1-3 UTR luciferase
reporter plasmids were kind gifts from Dr. Ahlquist. Paul [37]. For
the construction of mutant plasmid, the 29 base pair seed region of
the predicted miR-29 binding site was deleted from the above
parental constructs using QuickChange XL-mutagenesis (Strata-
gene). To construct Lims1-39UTR reporter plasmid, a 45 bp
fragment encompassing miR-29 binding site was cloned into
pMIR-report vector (ABI) between Spa1 and Sac1 sites. Mutant
reporter plasmids were generated by mutating the seed region
from TGGTGCT to TACCTCT. Replication-deficient lentivirus-
based expression plasmids pMIF-cGFP-Zeo Vector and pMIF-
cGFP-Zeo-miR-29b, along with the packaging plasmid mix
(pPACK), were obtained from System Biosciences (SBI). An
YY1 expression plasmid was a gift from Y. Shi (Harvard
Figure 6. A model of TGF-b-Smad3-miR-29 circuit in myogenic and fibrogenic differentiation of C2C12 myoblasts. The model depicts
the roles of the TGF-b-Smad3-miR-29 regulatory circuit in myogenic and fibrogenic differentiation of C2C12 cells. In the normal myogenesis, the
recruitment of MyoD/SRF and the displacement of YY1/PRC from miR-29 promoter lead to the elevation of miR-29 expression and its feedback
inhibition on YY1 and successful myogenic differentiation. Upon TGF-b stimulation, activated Smad3 translocates into nucleus where it binds to SBE,
resulting in MyoD dissociation as well as YY1/Ezh2 recruitment to multiple CCAT boxes of miR-29b/c promoter. This leads to trimethylation of histone
lysine 27 and subsequent silencing of miR-29 expression. Loss of miR-29 upregulates the expression of ECM genes such as Collagens as well as cell
adhesion genes such as Lims1, thus promoting the conversion of myoblasts into myofibroblasts. Straight line, promoter/enhancer region of mmu-
miR-29b/c with arrow denotes TSS; CCAT, YY1 binding elements; E-box, MyoD binding sites; SBE, Smad3 binding element; Me, methylation of histone
lysine 27; Ac, acetylation of histones.
doi:10.1371/journal.pone.0033766.g006
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plasmid was a gift from Prof. Lan Huiyao. MyHC and Troponin
luciferase reporter (MyHC-Luc and Troponin-Luc) were used as
described [25]. miR-29-promoter luciferase reporter was created
and used as described (Wang et al., 2008). Renilla luciferase
reporter was obtained from Promega and used according to
manufactory.
RT-PCR and Real-time RT-PCR
Total RNAs from cells were extracted using TRIzol reagent
(Invitrogen). Expression of mature miRNAs was determined using
the miRNA-specific Taqman microRNA assay kit (Applied
Biosystem) on an ABI PRISM 7900HT Sequence Detection
System (Applied Biosystem). U6 was used for normalization.
Expression of mRNA analysis was performed with SYBR Green




For Western blotting analyses, total cell extracts were prepared
and used as previously described [36]. The following dilutions
were used for each antibody: Myogenin (Santa Cruz Biotechnol-
ogy; 1:2000), YY1 (Santa Cruz Biotechnology; 1:2000), Troponin
(Sigma; 1:2000), MyHC (Sigma; 2,000), Smad 2 (cell signaling;
1:2000), Smad 3 (Abcam; 1:2000), Smad 7 (Santa Cruz; 1:2000),
Collagen 1 (Novus Biologicals, 1:2000), alpha Smooth Actin (a-
SMA, Millipore; 1:2000), a-Tubulin (Sigma; 1:5000), and
GAPDH (Santa Cruz Biotechnology; 1:5000). Immunofluores-
cence of cultured cells was performed using the following
antibodies: MyHC (Sigma; 1:350), Collagen 1 (Novus Biologicals,
1:350), a-SMA (Millipore, 1:400), Vimentin (Santa Cruz; 1:350),
MyoD (DAKO, 1:400). All fluorescent images were captured with
a confocal laser scanning microscope (FV1000, Olympus, Japan).
Fluorescence was detected with an Olympus microscope (FV1000,
Olympus, Tokyo, Japan). All samples were imaged with the 206
or 406objective lens. Pictures were captured in Kahlman frame
giving an average of two scans using the Olympus microscope
FV1000 and the accompanying software FV10-ASW (version
01.07.02.02, Olympus).
ChIP assays
ChIP assays were performed as recommended by the
manufacturer (Upstate) using 5 mg of antibodies against YY1
(Santa Cruz Biotechnology), Ezh2 (Cell signaling), trimethyl-
histone H3-K27 (Millipore), Smad 3 (Abcam), or isotype IgG
(Santa Cruz Biotechnology) used as a negative control. Genomic
DNA pellets were resuspended in 20 ml of water. qRT-PCR was
performed with 1 ml of immunoprecipitated material with SYBR
Green Master Mix (Bio-Rad Laboratories). Relative recruitment is
calculated as the amount of amplified DNA normalized to input
and relative to values obtained after normal IgG immunoprecip-








+/+ (CD-1 or ICR) and Smad 7
2/2 (Smad7
_exI mutant
mouse) mice were kind gifts from Prof. Lan Huiyao [38,39]. Mice
were housed in the animal facilities of The Chinese University of
Hong Kong (CUHK) under conventional conditions with constant
temperature and humidity and fed a standard diet. Animal
experimentation was approved by the CUHK Animal Ethics
Committee. Primary myoblasts were isolated from approximately
one week old mice muscles by the described procedures (Rando
and Blau, 1994). Briefly, total hind limb muscles (3 to 6 mice per
group) were digested with type IV collagenase (Invitrogen, 5 mg/
ml) and dispase II (Invitrogen, 1.4 mg/ml) for 0.5 hr, and cell
suspensions were further homogenized by pipetting before being
filtered through 70 mM and 40 mM filters. The obtained cells were
pre-plated on uncoated cell culture plates in F10 media
(Invitrogen) to selectively enrich for myoblasts. After two rounds
of pre-plating, the cell suspension was plated on Gelatin-coated
plates (Iwaki) in F10 medium (Invitrogen) supplemented with 20%
FBS and Basic Fibroblast Growth Factor (Invitrogen, 25 ng/ml).
Primary myoblasts were used at passage 3–5 after isolation. For
Cardiotoxin injection. Approximately five week old Smad7
+/+ or
Smad7
2/2 mice were injected with 60 ml of cardiotoxin (CTX) at
10 mg/ml into the tibialis anterior muscles. Muscles were
harvested at designated times, and total RNAs were extracted
for real-time RT-PCR analysis.
Sequencing and base calling
Preparation of transcription libraries for sequencing on the Illumina
GA2x platform was carried out using the mRNA-Seq Sample
Preparation Kit (Cat # RS-930-1001) according to the manufactur-
er’s standard protocol. Briefly, purified RNA was fragmented via
incubation for 5 min at 94uC with the Illumina-supplied fragmenta-
tion buffer. The first strand of cDNA was next synthesized by reverse
transcription using random oligo primers. Second-strand synthesis
was conducted by incubation with RNase H and DNA polymerase I.
The resulting double-stranded DNA fragments were subsequently
end-repaired, and A-nucleotide overhangs were added by incubation
with Taq Klenow lacking exonuclease activity. After the attachment
of anchor sequences, fragments were PCR-amplified using Illumina-
supplied primers and loaded onto the GA2x flow cell. DNA clusters
were generated with an Illumina cluster station with Paired-End
Cluster Generation Kit v2 (Illumina), followed by 5162c y c l e so f
sequencing on the GA2x (Illumina) with Sequencing Kit v3 (Illumina).
Genome Analyzer Sequencing Control Software (SCS) v2.5, which
could perform real-time image analysis and base calling, was used to
carry out the image processing and base calling during the chemistry
and imaging cycles of a sequencing run. The default parameters
within the data analysis software (SCS v2.5) from Illumina were used
to filter poor-quality reads. In the default setting, a read would be
removed if a chastity of less than 0.6 is observed on two or more bases
a m o n gt h ef i r s t2 5b a s e s .
Read mapping to genome with splice-aware aligner
Sequenced fragments were mapped to UCSC mouse reference
genome mm9 using TopHat version 1.1.4. Cufflinks version 1.0.0
was then used to estimate transcript abundances of RNA-Seq
experiments. Abundances were reported in FPKM (fragments per
kilobase of transcript per million fragments mapped) which is
conceptually analogous to the reads per kilobase per million reads
mapped (RPKM) used for single end RNA-seq.
Statistical analysis
Statistical significance was assessed by the Student’s t-test.
(*p,0.5; **p,0.01; ***p,0.001)
Supporting Information
Figure S1 RNA-seq reveals that miR-29 overexpression
leads to transcriptome change in C2C12 cells. Total RNAs
were isolated from NC or miR-29 expressing C2C12 cells and
subjected to high throughput mRNA sequencing (mRNA-seq).
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mouse reference genome (UCSC mm9). The normalized fragment
density was calculated by counting the fragments per kilobase of
genomic regions of interests (coding sequences (CDS), introns, 59
UTR, 39UTR, and non-coding (nc) exons) per million mapped reads.
In both NC (A) and miR-29 (B) samples, the majority of the RNA-seq
reads fall into the transcript regions (CDs, 59UTR, and 39UTR),
demonstrating good specificity for mRNAs. (C) The expression of
ECM genes, Col 1a1, Col 1a2, Col 3a1, Vimentin, as well as Lims1 in
NC and miR-29 expressing cells as revealed by RNA-seq. (D) miR-29
over-expression in 10T1/2 cells (Fibroblasts) leads to the down-
regulation of ECM synthesis. (E) miR-29 over-expression in 293 cells
leads to the down-regulation of Col 3a1 expression.
(TIF)
Figure S2 miR-29 down-regulates Collagens in C2C12
myoblasts. Col 1A1, Col 1A2 or Col 3A1 39UTR reporter
plasmid was transfected into C2C12 cells with indicated miRNA
oligos. Luciferase activities were determined at 48 h post-
transfection and normalized to b-Galactosidase protein. Relative
activity is shown with respect to control cells where normalized
luciferase values were set to 1. The data represents the average of
three independent experiments 6 S.D.
(TIF)
Figure S3 TGF-b inhibits miR-29 during myogenic and
fibrogenic differentiation of C2C12 cells. (A) C2C12 cells
were treated with 5 ng/ml of TGF-b in differentiation medium
(DM) for 0, 3 and 6 days. RNAs were isolated for qRT-PCR
measurement of the expressions of Myogenin, MyHC, a-Actin,
and Troponin normalized to GAPDH. Expression folds are shown
with respect to 0 hr cells where normalized copy numbers were set
to 1. Data are plotted as mean 6 S.D. (B) Cell morphology was
visualized under phase contrast. Bars=50 mm. (C) C2C12 cells
were transfected with 0.2 mg of Troponin-Luc reporter plasmids
along with Renilla reporter plasmid and treated with TGF-b for
48 hrs at which time luciferase activities were determined and
normalized to Renilla luciferase activity. Relative light unit (RLU)
is shown with respect to untreated cells where normalized
luciferase values were set to 1. The data represent the average of
three independent experiments 6 S.D. (D) C2C12 cells were
treated with TGF-b for 3 days. Proteins were isolated for Western
measurement of the expression of Cadherin-11, FSP1 (Fibroblast-
specific protein-1), Transgelin using Tubulin as a loading control.
(E) C2C12 cells were treated with TGF-b in DM for 0, 3, 6 days.
Total RNAs were isolated for qRT-PCR measurement of the
expression of Col 1A1, Col 1A2, Col 3A1, a-SMA or VIM
normalized to GAPDH. Expression folds are shown with respect
to 0 hr cells where normalized copy numbers were set to 1. Data
are plotted as mean 6 S.D. (F). C2C12 cells were treated with
TGF-b for 0, 1, 2 or 3 days and the viable cell number was
counted. Proliferation folds are shown with respect to day 0 cells
where normalized proliferation fold were set to 1. Data are plotted
as mean 6 S.D. (G) Left: C2C12 cells treated with TGF-b were
seeded on 6-well plate with 100% confluent monolayer and a
‘‘wound’’ was induced. Phase-contrast pictures of the wound were
taken at 0, 3, 6 and 9 hr. Right: The percentage of wound closure
was quantified at each indicated time point. (H) C2C12 cells were
treated with or without TGF-b in DM for four days. Cells were
fixed and stained for a-SMA (green). DAPI (blue) staining was also
performed to visualize the nuclei. Photos were taken by confocal
scanning microscope. (I) NC or miR-29 stable cells were untreated
(2) or treated (+) with TGF-b in DM for the indicated time
intervals at which time RNAs were isolated for qRT-PCR analysis
of Myogenin, Troponin, a-Actin and MyHC. Expression folds are
shown with respect to NC cells without TGF-b treatment where
normalized copy numbers were set to 1. Data are plotted as
mean 6 S.D.
(TIF)
Figure S4 miR-29 inhibits Smad3 expression. Basal and
phosphorylated (p) Smad3 levels were examined in C2C12 cells
over-expressing miR-29 or with miR-29 knock-down by Anti-miR
oligos. Tubulin was used as a loading control. The quantification
of Smad3 or p-Smad3/Tubulin was performed using ImageJ
1.43u (National Institutes of Health, USA). The expression folds
are shown with respect to control where normalized expression
fold were set to 1.
(TIF)
Table S1 List of up-regulated genes in miR-29 express-
ing C2C12 cells.
(PDF)
Table S2 List of down-regulated genes in miR-29
expressing C2C12 cells.
(PDF)
Table S3 Functional annotation clustering of up-regu-
lated genes in miR-29 expressing C2C12 cells.
(XLS)
Table S4 Functional annotation clustering of down-
regulated genes in miR-29 expressing C2C12 cells.
(XLS)
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